2023年3月7日,来自江苏常州武进区的常州中进医疗器材股份有限公司的实质控股股东 JIN MEDICAL INTERNATIONAL LTD.(以下简称“中进医疗”)向美国证监会(SEC)交更新后的股书,拟在美国纳斯达克上市,其股票代码为 ZJYL 。其于2020年12月28日在SEC秘密递表。


中进医疗,拟以每股8至9美元发行125万股普通股,募资或达1,125万美元。


中进医疗招股书链接:

https://www.sec.gov/Archives/edgar/data/1837821/000121390023014263/ea173808-f1a11_jinmedical.htm



主要业务

中进医疗,成立于2006年,作为一家医疗器材制造商,主要为残疾人、老年人和伤病康复者设计、制造轮椅和生活辅助产品(包括助行类、呼吸类医疗器材、智能纳米洗浴设备以及老年人、病人专用的乐浴系列产品、老年人及特殊人群的健身器材、救灾抢险等)


中进医疗的产品大部分销售给日本和中国的经销商,少部分销往美国、加拿大、澳大利亚、韩国、以色列、新加坡等。



股东架构

招股书显示,招股书显示,中进医疗在上市前的股东架构中,控股股东为王尔琪先生,持股87.44\%,其通过Jolly Harmony Enterprises(王尔琪持100\%)持股78.74\%、通过Er Pu International(王尔琪持64.625\%)持股8.70\%。

Gorgeous Abundant Enterprises,持股8.59\%。



公司架构

招股书显示,中进医疗的公司架构如下:




管理层

招股书显示,中进医疗的管理层如下:


Mr. Erqi Wang has been our CEO and Chairman of the board of directors since January 2020, and he has served as CEO and Chairman of Changzhou Zhongjin since he founded the company in October 2006. Mr. Wang is also a core leader of our R&D department. Previously, from July 2009 to March 2018, Mr. Wang served as the managing director of Sangui Rehabilitation Equipment (Shanghai) Co., Ltd. Currently, he also serves as the Honorary Vice President of Jiangsu Welfare Foundation for the Disabled and is a member of the China Wheelchair Association Mr. Wang has received a number of awards in China for his achievements as an entrepreneur and as a scientist, including the “Leading Entrepreneurial Talent in Changzhou City” in 2013, and the “Silver Medal in the First Jiangsu Industrial Design Competition” in 2008. Mr. Wang holds a PhD in Engineering Mechanics from Tohoku University, and owns 16 invention patents as the first inventor.
 
Mr. Ziqiang Wang has served as our CFO since January 2020, as our director since December 2021, and as the CFO of Changzhou Zhongjin since May 2008. Previously, from January 2006 to April 2008, he served as the CFO of Nikoda (Changzhou) Electric Co., Ltd; from January 1996 to December 2005, he served as the manager of the financial department at Changzhou Servo Motor Co., Ltd.; and from August 1992 to December 1995, he served as a financial officer at Changzhou BMW Group. Mr. Wang graduated from Hangzhou Institute of Electronic Technology with a Bachelor’s degree in Industrial Management in 1992, and was certified as a Senior Economist by the Department of Human Resources and Social Security of Jiangsu Province in 2013.




公司业绩

招股书显示,在过去的2021财年、2022财年(财政年度截止日期为9月30日)中进医疗的收入分别为2,076.43万、1,919.05万美元,相应的净利润分别为263.17万、270.65万美元。




中介机构

中进医疗是次IPO的的中介团队主要有:质数资本 Prime Number Capital为其承销商;Marcum Asia CPAs LLP/Friedman LLP为其审计师;大成、翰博文分别为其公司中国律师、公司美国律师;Kaufman & Canoles, P.C.分别为其承销商美国律师。



版权声明:所有瑞恩资本Ryanben Capital的原创文章,转载须联系授权,并在文首/文末注明来源、作者、微信ID,否则瑞恩将向其追究法律责任。部分文章推送时未能与原作者或公众号平台取得联系。若涉及版权问题,敬请原作者联系我们。

更多香港IPO上市资讯:www.ryanbencapital.com

相关阅读

中概股美国上市:14家IPO,12家借壳SPAC,至少47家正在上市排队中(2022年)

震坤行 ZKH,在美国SEC递交招股书,拟纽交所IPO上市

盛丰物流,来自福建福州,在美国SEC更新招股书,拟纳斯达克IPO上市

宝泰控股,来自福建福州,在美国SEC更新招股书,拟纳斯达克IPO上市

宏力型钢,来自山东潍坊昌乐,美国纳斯达克IPO路演PPT(18页)

能链Newlink,传弃港赴美国IPO上市

依生生物,弃港赴美、拟借壳SPAC在纳斯达克挂牌上市 (PPT 37页)


hkmipo

作者 hkmipo

发表回复